FibroGen's pamrevlumab fails Phase 3 DMD study in non-ambulatory patients; primary endpoint not met

KYNTRA BIO, INC.

Phase 3 LELANTOS-1 study of pamrevlumab in non-ambulatory DMD patients did not meet primary endpoint (PUL 2.0 score at week 52).
Pamrevlumab was generally safe and well tolerated; most adverse events were mild or moderate.
Topline results from LELANTOS-2 Phase 3 study in ambulatory DMD patients expected in Q3 2023.
CEO Enrique Conterno expressed disappointment and thanked patients, caregivers, and investigators.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.